Skip to content

Amylyx Pharmaceuticals

US · AMLX #2392 by market cap Listed 2022
26.02 -0.18 -0.69%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $57
    Market Newswire · 2026/8/27
  • Rating change
    H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/8/20
  • Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Cuts Target Price to $38
    Market Newswire · 2026/10/29
  • Rating change
    Baird Initiates Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $28
    Market Newswire · 2026/8/7
  • Rating change
    Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/8/17
  • Rating change
    A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $24 to $34
    Market Newswire · 2026/8/7
  • Rating change
    Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $26
    Market Newswire · 2026/8/4
  • Rating change
    TD Cowen Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating
    Market Newswire · 2026/8/19
  • Rating change
    Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $55
    Market Newswire · 2026/8/19
  • Rating change
    LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/7/30
  • Rating change
    LifeSci Capital Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $44
    Market Newswire · 2026/8/23
  • Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q3 Loss $0.38 a Share, Vs. FactSet Est of $0.37 Loss
    MT Newswires · 2026/11/5
  • H.C. Wainwright Initiates Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $55
    Market Newswire · 2026/11/6
  • Rating change
    Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $26
    Market Newswire · 2026/8/3
  • Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $39
    Market Newswire · 2026/11/6
  • Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $39
    Market Newswire · 2026/11/10
  • Rating change
    Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/8/20
  • Rating change
    Stifel Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $45
    Market Newswire · 2026/10/1
  • Rating change
    A Quick Look at Today's Ratings for Amylyx Pharmaceuticals(AMLX.US), With a Forecast Between $32 to $55
    Market Newswire · 2026/8/19
  • Rating change
    Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $39
    Market Newswire · 2026/10/15
  • Rating change
    H.C. Wainwright Initiates Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Announces Target Price $34
    Market Newswire · 2026/7/2
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Heart Test Laboratories, Inc. (HSCS) and Align Tech (ALGN)
    TipRanks · 2026/7/30
  • Citi Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $39
    Market Newswire · 2026/10/16
  • Rating change
    Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $24
    Market Newswire · 2026/7/20
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN)
    TipRanks · 2026/7/2

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Amylyx Pharmaceuticals discussion 0 comments

Add a comment